Keros Therapeutics, Inc. (KROS)
Nasdaq: KROS · Pharmaceutical Preparations · Lexington, MA · filing with the SEC since 2016
Who owns Keros Therapeutics, Inc.
As filed with the SECHolders of 5% or more
3
BlackRock Portfolio Management LLC holds 9.1% of Common Stock, as its SCHEDULE 13G/A filed Oct 27, 2026 says.
Directors and officers
18
report now, of 24 people on the record since 2020. Their holdings as a group are not read here.
Institutions as a whole
n/a
The record does not read the share held by managers that file Form 13F, so none is printed and no split of the rest is estimated. What it holds is the 3 named at left.
Holders of 5% or moreshare of the class, as filed
BlackRock Portfolio Management LLC
SCHEDULE 13G/A · filed Oct 27, 2026 · Common Stock · 5.7% in Jul 17, 2026
Blackrock, Inc.
SCHEDULE 13G/A · filed Jul 29, 2026 · Common Stock · 10.1% in Apr 7, 2026
Nantahala Capital Management, LLC
SCHEDULE 13G · filed May 15, 2026 · Common Stock, $0.0001 par value per share
D. E. Shaw & Co., L.P.
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 5.1% in Oct 27, 2025
Madison Avenue International LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share (the "Common Stock") · reported falling below 5%, from 6.4% in May 14, 2025
Alkeon Capital Management LLC
SCHEDULE 13G · filed Feb 14, 2025 · Common Stock, par value $0.0001 per share · reported falling below 5%
Fmr LLC
SCHEDULE 13G/A · filed Feb 7, 2025 · COMMON STOCK · reported falling below 5%
JPMorgan Chase & Co.
SCHEDULE 13G/A · filed May 5, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6.3% in May 2, 2025
ExodusPoint Capital Management, LP
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 6.3% in Nov 18, 2025
The Vanguard Group
SCHEDULE 13G/A · filed Mar 27, 2026 · Common Stock · reported falling below 5%, from 5% in Jan 30, 2026
Tang Capital Management, LLC
SCHEDULE 13G/A · filed Feb 17, 2026 · Common Stock, par value $0.0001 per share · reported falling below 5%, from 7.9% in Oct 22, 2025
Pontifax Management 4 GP (2015) Ltd.
SCHEDULE 13D/A · filed Oct 16, 2025 · Common Stock, Par Value $0.0001 Per Share · reported falling below 5%, from 11.8% in Apr 18, 2025
ADAR1 Capital Management, LLC
SCHEDULE 13D/A · filed Oct 15, 2025 · Common Stock, $0.0001 par value per share · reported falling below 5%, from 13.3% in Aug 21, 2025
What KROS reports owning in othersstakes of 5% or more, and other ties
2 subsidiaries in 2 countries, from the list filed with the 10-K filed Mar 4, 2026.
Insider tradesForm 4
12sales
6purchases
5sales on a scheduled plan
9people selling
$500,000sold, in dollars
$100,000bought, in dollars
Open-market trades on Form 4 from Sep 30, 2025 to Sep 30, 2026. A scheduled plan is a selling program set in advance under SEC rule 10b5-1. The trades are listed as filed and do not feed the grade.
By calendar yearSoldBought
2026 runs to Sep 30, 2026. Dollars as filed, summed by the transaction date.
People who traded in the window12 of 37 on the roster
| Person | Role as filed | Sales | Sold | On a plan | Buys | Bought |
|---|---|---|---|---|---|---|
| Schneeberger Daniel | 10% owner | 3 | $95.7M | 0 | 0 | $0 |
| Pontifax (China) IV L.P. | 10% owner | 4 | $85.0M | 0 | 0 | $0 |
| Seehra Jasbir | CHIEF EXECUTIVE OFFICER | 1 | $100,000 | 0 | 0 | $0 |
| Regnante Keith | CHIEF FINANCIAL OFFICER | 1 | $100,000 | 0 | 0 | $0 |
| Cho Esther | Chief Legal Officer | 2 | $100,000 | 0 | 0 | $0 |
| Lerner Lorena Raquel | Chief Scientific Officer | 2 | $100,000 | 0 | 0 | $0 |
| Bienaime Jean Jacques | director | 0 | $0 | 0 | 6 | $100,000 |
| Tanini Annita | Corp. Controller & VP, Finance | 1 | $0 | 0 | 0 | $0 |
| Newton Charles W. | director | 2 | $0 | 2 | 0 | $0 |
| Farzan Nima | director | 1 | $0 | 1 | 0 | $0 |
| Knowles Julius | director | 1 | $0 | 1 | 0 | $0 |
| Seth Alpna | director | 1 | $0 | 1 | 0 | $0 |